2.465USD-1.40%Mkt Cap: 156.98M USDP/E: —Last update: 2026-05-26
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune ago…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap156.98M USD
Enterprise Value143.45M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-30.05M USD
Revenue/Share—
Last Price2.465 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees22
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.03
PEG—
EV/EBITDA-4.95
EV/Revenue—
P/S—
P/B6.72
EPS (TTM)-0.61
EPS (Forward)-0.58
52W Range
0.410059% of range3.900
52W High3.900 USD
52W Low0.4100 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-143.57%
ROA-109.87%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-27.63M USD
CapEx (TTM)76.08K USD
FCF Margin—
FCF Yield-1.03%
Net Debt-5.84M USD
Net Debt/EBITDA0.20
Balance Sheet
Debt/Equity0.03
Current Ratio1.15
Quick Ratio1.07
Book Value/Sh0.3480 USD
Cash/Share0.0990 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:35
Split DateOct 18, 2024
Analyst Consensus
Rating—
Target (Mean)8.400 USD
Target Range7.000 USD – 10.00 USD
# Analysts5
Ownership
Shares Out.63.68M
Float35.44M
Insiders34.88%
Institutions14.97%
Short Interest
Short Ratio6.3d
Short % Float16.82%
Short % Out.12.97%
Shares Short8.26M
Short (prev mo.)7.49M
Technical
SMA 502.229 (+10.6%)
SMA 2001.931 (+27.6%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)885.53K
Avg Vol (10d)538.87K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—